Guide
Constipation on a GLP-1: Mechanism, Incidence and the Line to Watch
Constipation was reported by 17% of participants at tirzepatide 15 mg in SURMOUNT-1. It follows directly from slowed gastric emptying and reduced food volume, and it is u
Constipation was reported by 17% of participants at tirzepatide 15 mg in SURMOUNT-1. It follows directly from slowed gastric emptying and reduced food volume, and it is usually manageable — but the label flags ileus, and the distinction between slow bowels and an obstruction is one worth understanding before you need it.
What was recorded
In SURMOUNT-1 at 15 mg, constipation was reported by 17% of participants, alongside diarrhoea at 23% and dyspepsia at 10%. Both directions of bowel change occur, sometimes in the same person at different points in titration.
Why it happens
Two mechanisms combine. These drugs slow gastric emptying, which slows transit through the digestive tract. And reduced appetite means less food volume and often less fibre and fluid, which independently slows things further.
So it is partly pharmacological and partly a downstream consequence of eating less — which is why the useful conversation covers both dose and intake rather than only one.
The line that matters
The prescribing information for these drugs notes ileus — a functional obstruction where the bowel stops propelling contents forward. It has been reported in postmarketing use.
Ordinary constipation is uncomfortable and slow. Ileus presents differently: significant abdominal distension, severe pain, persistent vomiting, and an inability to pass stool or gas at all. That combination is a reason for urgent assessment rather than patience.
We are drawing this line explicitly because the two are described with the same everyday word, and the distinction is the clinically important part of this page.
Expected, contact, urgent
Expected: less frequent bowel movements, harder stool, some straining, particularly after a dose increase and while intake is lower than usual.
Contact your prescriber: constipation persisting beyond a few days despite the usual measures, significant discomfort, or a pattern that worsens with each dose increase.
Urgent: severe abdominal pain with distension, vomiting, and inability to pass stool or gas.
What we will not do here
Recommend specific laxatives, fibre products or doses. Those interact with other medications, some are inappropriate with certain conditions, and the choice depends on what is actually causing the problem in your case. A pharmacist can advise on this quickly and knows what else you take.
What is worth saying generally is that adequate fluid intake matters more than usual when transit is slowed, and that this is harder when appetite suppression has reduced everything you consume, including drinks.
What to track
- Whether it started or worsened at a specific dose step.
- Whether it alternates with diarrhoea, which is common and worth mentioning.
- How much you are drinking, honestly.
- Whether anything else changed — new medications, particularly iron or opioids, compound this significantly.
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Questions readers actually ask
Is constipation common on GLP-1s?
Constipation was reported by 17% of participants at tirzepatide 15 mg in SURMOUNT-1, alongside diarrhoea at 23%. Both directions of bowel change occur.
What is ileus and how is it different?
Ileus is a functional obstruction noted in the prescribing information. Unlike ordinary constipation it presents with significant distension, severe pain, vomiting and inability to pass stool or gas — a reason for urgent assessment.
Why does it happen?
Slowed gastric emptying slows transit, and reduced appetite means less food volume, fibre and fluid. It is partly pharmacological and partly a consequence of eating less.
What should I take for it?
That depends on your other medications and conditions, so ask a pharmacist or your prescriber rather than a website. Adequate fluid intake matters more than usual when transit is slowed.
Related on this site
- The 100-point rubricCore & Trust
- Cost calculatorTools
- The underlying price recordsData
- Henry Meds Tirzepatide ReviewProviders
- GLP-1 and Tirzepatide NewsNews
- GLP-1 and Tirzepatide JournalJournal
- GLP-1 Weight Loss and Muscle PreservationJournal
- GLP-1 Telehealth vs Local Weight-Loss ClinicComparisons
- GLP-1 Data API DocumentationData
- Tirzepatide Price Comparison by ProviderPillar / Money
Related coverage
GLP-1 Tirzepatide Review. “Constipation on a GLP-1: Mechanism, Incidence and the Line to Watch.” S.J Partners LLC, 2026-07-26. https://glptirzepatidereview.com/side-effects/constipation/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.